Autolus lifts AUCATZYL outlook as third-quarter sales rise 95%

Autolus Therapeutics plc (NASDAQ: AUTL) reported third-quarter 2026 AUCATZYL net product revenue of $41.2 million, up 95% from $21.1 million, and raised its full-year outlook. The $20.1 million increase reflected stronger demand at existing authorized treatment centers, new centers and UK sales.

At centers already offering AUCATZYL, physicians were building positive experience, CEO Dr. Christian Itin said: “Growth came mainly from existing authorized treatment centers as physicians gain positive experience.” He also called AUCATZYL’s performance in adult leukemia “a key near-term value driver.” The FDA approved the therapy on Nov. 8, 2024, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

What is driving the sales increase?

Nine-month AUCATZYL revenue reached $113.1 million, up 122% from $51.05 million in the same period of 2025. Autolus investor slides showed 90 authorized U.S. treatment centers and marked the company’s 2026 goal of more than 80 centers as achieved. Itin pointed to real-world data from the ROCCA consortium, with more data expected in December.

The network is broadening, and December’s ROCCA update will add evidence behind the sales rise.

How much revenue does the raised outlook require?

Autolus now expects full-year 2026 AUCATZYL net product revenue at or above the top of its prior guidance range. OptimistFi calculated that reaching the $150 million outlook requires at least $36.9 million of fourth-quarter revenue, below the $41.2 million delivered in the third quarter.

On that arithmetic, the raised outlook does not require further sequential growth. The nine-month total has already brought the revenue threshold within reach.

The final-quarter revenue hurdle now sits below the level Autolus just cleared.

How did margins and operating costs change?

• Gross margin: 57% in the third quarter, up from 55% in the second quarter and no longer negative as in the third quarter of 2025. Year-to-date gross margin was 44%, while the slides set a peak target of 65% to 70%.
• Cost of sales: $17.9 million, down from $28.6 million, even as revenue rose. Autolus said higher volumes and efficiency work lowered manufacturing cost per batch, while inventory reserves and write-offs also fell.
• Research and development: $30.9 million, up from $27.9 million, which the company tied to higher clinical manufacturing supply costs. Selling, general and administrative expenses slipped to $35.9 million from $36.3 million.
• Operating loss: $43.5 million, compared with $71.6 million, a 39.2% narrowing. Net loss was $55.1 million, or $0.21 per share, against $79.1 million, or $0.30. Other expenses, net, rose to $12.0 million from $7.0 million.

Better gross profit narrowed the operating loss, though research spending and other expenses still weighed on net results.

Can cash carry the plan into 2028?

Cash, cash equivalents and marketable securities stood at $248.4 million at Sept. 30, up from $201.6 million at June 30. Autolus said the increase came mainly from net cash inflows under its senior secured note facility with Perceptive Advisors.

The company expects that liquidity to fund operations into Q2 2028, using the first and second tranches of the facility, worth $100 million combined, and anticipated AUCATZYL revenue. The estimate assumes current operating plans and revenue still to be earned, so the runway rests partly on debt proceeds and future sales. The raised revenue outlook remains guidance, not realized revenue.

Total shareholders’ equity fell to $27.4 million at Sept. 30 from $178.1 million at Dec. 31, 2025, an 84.6% drop calculated by OptimistFi. Total liabilities rose to $495.7 million from $410.9 million.

OptimistFi argued that AUCATZYL must achieve real-world adoption and positive unit economics before the balance sheet forces dilution. The quarter supports both conditions through center growth and a positive gross margin. On balance, the quarter strengthens the operating case, but the financing question remains open.

Cash rose. The equity base did not.

Liquidity improved, but the smaller equity cushion leaves financing as a live issue.

What evidence comes next?

• AUTO8: Initial Phase 1 data from the ALARIC trial in light-chain amyloidosis are expected at ASH on Dec. 12.
• CARLYSLE: Updated lupus data were scheduled for the American College of Rheumatology meeting on Nov. 10, with up to 25 months of follow-up in adults.
• BOBCAT: First data in progressive multiple sclerosis are slated for the ECTRIMS Global meeting in October 2027. Key opinion leaders want longer follow-up; Autolus expects at least 12 months for the first 12 patients and data in up to 24 patients.
• CATULUS: Phase 2 pediatric leukemia data are expected by year-end 2027.
• LUMINA: Phase 2 lupus nephritis data are expected in 2028.

AUCATZYL supports revenue and margins now; five scheduled updates will show whether the other programs add future value.